Dirk Blom - Researcher Profile | RDL Research Database

Publications

2 shown

Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

Marc S. Sabatine , Robert P. Giugliano , Stephen D. Wiviott +10 more

Evolocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9), significantly reduced low-density lipoprotein (LDL) cholesterol levels in ...

2015 New England Journal of Medicine 1463 citations

A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia

Dirk Blom , Tomas Hala , Michael A. Bolognese +13 more

At 52 weeks, evolocumab added to diet alone, to low-dose atorvastatin, or to high-dose atorvastatin with or without ezetimibe significantly reduced LDL cholesterol levels in pat...

2014 New England Journal of Medicine 697 citations

Frequent Co-Authors

Researcher Info

h-index: 2
Publications: 2
Citations: 2,160
Institution: University of Cape Town

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0003-3965-5912

Impact Metrics

h-index 2

h-index: Number of publications with at least h citations each.